Tesaro, Inc. (TSRO): Jeffrey H. Hanke , Executive VP, R&D and CSO of Tesaro, Inc. sold 12,500 shares on Jun 30, 2016. The Insider selling transaction was reported by the company on Jul 1, 2016 to the Securities and Exchange Commission. The shares were sold at $74.02 per share for a total value of $929,321.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 14, 2016, Edward C English (VP of Finance & Administration) sold 7,000 shares at $41.21 per share price.On Mar 18, 2016, Beth C Seidenberg (director) purchased 1,420,858 shares at $35.19 per share price.Also, On Mar 18, 2016, Arnold L Oronsky (director) purchased 142,085 shares at $35.19 per share price.On Sep 9, 2015, James O Armitage (director) purchased 500 shares at $54.63 per share price.
TESARO Inc: On Wednesday, Jun 29, 2016 heightened volatility was witnessed in TESARO Inc which led to swings in the share price. The shares opened for trading at $68.78 and hit $80.69 on the upside , eventually ending the session at $77.4, with a gain of 108.01% or 40.19 points. The heightened volatility saw the trading volume jump to 1,90,94,609 shares. The 52-week high of the share price is $80.69 and the company has a market cap of $3,548 M . The 52-week low of the share price is at $29.51.
Company has been under the radar of several Street Analysts.TESARO Inc is Downgraded by Jefferies to Hold. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Jun 30, 2016.TESARO Inc is Reiterated by FBR Capital to Outperform and the brokerage firm has raised the Price Target to $ 93 from a previous price target of $65 .The Rating was issued on Jun 29, 2016.TESARO Inc is Initiated by Credit Suisse to Outperform. The Rating was issued on May 13, 2016.TESARO Inc is Initiated by FBR Capital to Outperform and the brokerage firm has set the Price Target at $65. The Rating was issued on Apr 13, 2016.
TESARO Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates rolapitant niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1 or NK-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib formerly known as MK-4827 is an orally active and potent poly (ADP-ribose) polymerase and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio Inc. for the discovery and development of antibodies for several specified immuno-oncology targets.